WJWei Jiang

Wei Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Jiang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Governing Patient-Facing AI-Generated Video in Digital Health: A Risk-and-Ethics Matrix for Deployment, Monitoring, and Change Control

    by Yongzheng Hu, Wei Jiang

    In this Viewpoint, we argue that patient-facing high-fidelity artificial intelligence (AI)–generated video requires governance that is operational, life cycle based, and embedded in existing institutional review pathways rather than limited to predeployment checks alone. Patient-facing high-fidelity AI-generated video—synthetic or substantially AI-mediated video that presents realistic human likeness, voices, or clinical communication cues—is rapidly entering patient education and clinical communication. We propose a risk-and-ethics matrix that combines residual clinical risk (likelihood × severity after mitigations) with an ethical alignment score that operationalizes autonomy, beneficence, nonmaleficence, and justice to yield actionable dispositions (encourage, permit with oversight, restrict or redesign, or prohibit). The framework links each disposition to dossier-based review, minimum controls, and postdeployment monitoring triggers—focused on measurable outcomes (eg, comprehension, content-attributable follow-up burden, incidents and complaints, and equity gaps) as well as provenance and change control—to support auditable, revisitable decisions over the system life cycle.


  • Open Access

    Artificial intelligence virtual cells as a new paradigm in nephrology: from multiomics integration to clinical translation

    by Yongzheng Hu, Yabin Wang, Xinyue Qi, Wei Jiang

    Kidney diseases remain heterogeneous and mechanistically complex, and current experimental models only partially capture patient-specific dynamics. We advance artificial-intelligence virtual cells (AIVCs) as a translational framework that learns cross-modal representations of renal cell states, performs high-throughput in silico perturbations, and improves via experiment-in-the-loop updates with organoid and real-world readouts. We outline a methodological pathway-data, representation, intervention, evaluation, deployment-anchored to atlas-grade tissue references (e.g., Kidney Precision Medicine Project) and complementary Human Cell Atlas resources, paired molecular-clinical cohorts, and minimally invasive urinary modalities to enable longitudinal, patient-centered modeling. AIVCs complement physical cells: molecular signals are harmonized into uncertainty-calibrated latent states; counterfactual simulations explore dose-time-context responses; and multicellular interactions are formalized as testable niche dynamics. To address competence and trust, we adopt a risk-proportionate verification-validation-uncertainty perspective aligned with contemporary guidance, emphasizing multisite external validation, counterfactual validity on held-out perturbations, probabilistic calibration with decision utility, and subgroup fairness auditing. Clinically, we map opportunities across mechanism reconstruction, individualized treatment-response prediction, nephrotoxicity triage, trial emulation, and routes toward kidney digital twins. Finally, we propose a practical AIVC-organoid partnership-simulate → experiment → validate → iterate-to prioritize hypotheses, shrink the experimental search space, and link mechanistic evidence to bedside decisions. By integrating representation learning, virtual experimentation, and continual updating with interoperable data standards and governance, AIVCs offer an actionable roadmap for precision nephrology.


  • Open Access

    Association between red blood cell distribution width-to-albumin ratio and chronic kidney disease: A cross-sectional study

    by Jie Li, Yabin Wang, Xinyi Hao, Wei Jiang

    To investigate the association between red cell distribution width-to-albumin ratio (RAR) and chronic kidney disease (CKD) prevalence in the general adult population in the United States, where relevant evidence remains scarce. This cross-sectional study used data from the National Health and Nutrition Examination Survey spanning 2005 to 2018. Eligible participants were adults aged ≥ 20 years with complete data on RAR and CKD. Weighted multivariate logistic regression models, adjusted for demographics (age, sex, and race), lifestyle (smoking, alcohol consumption), metabolic indicators (body mass index, glucose, and lipids), and comorbidities (hypertension and diabetes) were used to assess the RAR–CKD association. Restricted cubic spline and subgroup analyses were performed to evaluate the nonlinearity and stability of the results, respectively. Receiver operating characteristic curve analysis was performed to determine the predictive ability of RAR for CKD. Among the 29,847 participants, a significant positive association was observed between higher RAR and increased CKD prevalence after full adjustment. Restricted cubic spline analysis confirmed a positive nonlinear relationship between the two. Subgroup analyses (stratified by sex, race, body mass index, and comorbidities) revealed heterogeneity in the strength of the association, while the positive direction remained consistent across all subgroups. Additionally, the receiver operating characteristic curve analysis demonstrated that RAR has a certain predictive ability for CKD. Elevated RAR is significantly associated with a higher prevalence of CKD in American adults. As an easily accessible biomarker reflecting integrated inflammatory and nutritional status, RAR holds the potential for early CKD risk assessment and the development of personalized management strategies.


  • Open Access

    Beyond burden: a Quality of Care Index (QCI) assessment of hepatitis B in 204 countries, 1990-2021

    by Yongzheng Hu, Xinyue Qi, Yan Jiang, Wei Jiang

  • Open Access

    Artificial intelligence for mechanistic understanding of hepatitis B virus

    by Yongzheng Hu, Wei Jiang

    Chronic hepatitis B virus (HBV) persists through a compact proteome, deep reliance on host pathways, and a nuclear covalently closed circular DNA (cccDNA) reservoir that current antivirals rarely extinguish. This Mini Review synthesizes advances from 2020–2025 in which artificial intelligence (AI) augments mechanistic understanding of HBV rather than serving only predictive ends. We summarize (i) AI-enabled structural modeling that clarifies polymerase priming and HBx architecture; (ii) physics-informed and multiscale inference that links sparse measurements to replication and cccDNA kinetics; (iii) sequence-based learners that expose non-random host-genome integration contexts and mutational constellations associated with immune tolerance or escape; (iv) network-aware analyses that prioritize host dependencies and connect CRISPR perturbations to virus–host modules governing cccDNA transcriptional control; and (v) AI-assisted antiviral discovery that couples virtual screening with mechanism-anchored interpretation (e.g., capsid assembly modulators). Across these domains, AI sharpens hypotheses by mapping viral mutations and host factors to discrete steps of the life cycle, quantitatively elevating high-leverage processes such as nucleocapsid recycling and cccDNA silencing, and guiding structure- or phenotype-guided intervention design. We also outline practical constraints—data sparsity, cross-cohort heterogeneity, and interpretability—and propose priorities that couple computation and experiment: mechanism-aware gray-box models, causal and spatially resolved analyses, calibrated uncertainty and benchmarking across genotypes, and active-learning loops that maximize information gained per experiment. Framed this way, AI emerges as a mechanism-aware partner to experimental virology, accelerating routes toward durable functional cure through eradication or stable transcriptional silencing of cccDNA.


  • Open Access

    Large language models in nephrology: applications and challenges in chronic kidney disease management

    by Yongzheng Hu, Jianping Liu, Wei Jiang

    Large language models (LLMs) represent a transformative advance in artificial intelligence, with growing potential to impact chronic kidney disease (CKD) management. CKD is a complex, highly prevalent condition requiring multifaceted care and substantial patient engagement. Recent developments in LLMs-including conversational AI, multimodal integration, and autonomous agents-offer novel opportunities to enhance patient education, streamline clinical documentation, and support decision-making across nephrology practice. Early reports suggest that LLMs can improve health literacy, facilitate adherence to complex treatment regimens, and reduce administrative burdens for clinicians. However, the rapid deployment of these technologies raises important challenges, including patient privacy, data security, model accuracy, algorithmic bias, and ethical accountability. Moreover, real-world evidence supporting the safety and effectiveness of LLMs in nephrology remains limited. Addressing these challenges will require rigorous validation, robust regulatory frameworks, and ongoing collaboration between clinicians, AI developers, and patients. As LLMs continue to evolve, future efforts should focus on the development of nephrology-specific models, prospective clinical trials, and strategies to ensure equitable and transparent implementation. If appropriately integrated, LLMs have the potential to reshape the landscape of CKD care and education, improving outcomes for patients and supporting the nephrology workforce in an era of increasing complexity.


  • Open Access

    Identification of novel therapeutic targets in hepatitis-B virus-associated membranous nephropathy using scRNA-seq and machine learning

    by Yongzheng Hu, Qian An, Xinxin Yu, Wei Jiang

    Hepatitis B Virus-associated membranous nephropathy (HBV-MN) significantly impacts renal health, particularly in areas with high HBV prevalence. Understanding the molecular mechanisms underlying HBV-MN is crucial for developing effective therapeutic strategies. This study aims to elucidate the roles of miR-223-3p and CRIM1 in HBV-MN using single-cell RNA sequencing (scRNA-seq) and machine learning. scRNA-seq analysis identified a distinct subcluster of podocytes linked to HBV-MN progression. miR-223-3p emerged as a critical regulatory molecule, with overexpression resulting in decreased CRIM1 expression. Dual-luciferase reporter assays confirmed miR-223-3p targeting CRIM1 at a conserved binding site. These findings were corroborated by machine learning models, which highlighted the significance of miR-223-3p and CRIM1 in disease pathology. miR-223-3p plays a pivotal role in modulating CRIM1 expression in HBV-MN, providing a potential therapeutic target. Integrating scRNA-seq with machine learning offers valuable insights into the molecular landscape of HBV-MN, paving the way for novel interventions.


  • Open Access

    Integrative analysis of mitochondrial and immune pathways in diabetic kidney disease: identification of AASS and CASP3 as key predictors and therapeutic targets

    by Xinxin Yu, Yongzheng Hu, Wei Jiang

    Diabetic kidney disease (DKD) is driven by mitochondrial dysfunction and immune dysregulation, yet the mechanistic interplay remains poorly defined. This study aimed to identify key molecular networks linking mitochondrial and immune pathways to DKD progression, with a focus on uncovering biomarkers and therapeutic targets. We conducted an integrative analysis of human DKD cohorts (GSE30122, GSE96804) using weighted gene co-expression network analysis (WGCNA) to identify gene modules enriched for immune response genes and mitochondrial pathways (from MitoCarta3.0). Machine learning algorithms were employed to prioritize key biomarkers for further investigation. Experimental validation was performed using a DKD rat model. WGCNA revealed significant gene modules associated with immune responses and mitochondrial functions. Machine learning analysis highlighted two central biomarkers: aminoadipate-semialdehyde synthase (AASS) and caspase-3 (CASP3). In the DKD rat model, elevated levels of AASS and CASP3 were found to correlate with increased oxidative stress. Mechanistically, AASS was shown to drive mitochondrial damage via lysine metabolism, while CASP3 amplified inflammatory apoptosis pathways. Our findings establish AASS and CASP3 as dual biomarkers and therapeutic targets, bridging mitochondrial-immune crosstalk to DKD pathogenesis. This multi-omics framework provides actionable insights for targeting kidney damage in diabetes.


  • Open Access

    Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments

    by Yongzheng Hu, Yue Zhang, Wei Jiang

    Hepatitis B virus (HBV) infection remains a major global health challenge, affecting approximately 296 million people and causing significant mortality annually. Despite vaccination efforts, HBV prevalence persists, particularly in low- and middle-income regions and endemic areas like China. HBV is closely associated with various kidney diseases, including acute kidney injury, chronic kidney disease, and glomerulonephritis, through mechanisms such as immune complex deposition, direct viral invasion, and chronic inflammation. Patients undergoing hemodialysis or kidney transplantation are at increased risk of HBV infection and reactivation, highlighting the need for effective preventive and therapeutic measures. This review examines the classification and clinical features of HBV-associated nephropathy, focusing on membranous nephropathy and membranoproliferative glomerulonephritis. It explores the pathogenesis, emphasizing immune complex deposition and podocyte apoptosis. Antiviral therapy, particularly with nucleos(t)ide analogs like entecavir and tenofovir (including TAF and TMF), demonstrates superior efficacy and safety compared to older agents such as lamivudine and adefovir. While interferon therapy offers benefits, its use is limited by adverse effects. Additionally, individualized treatment strategies for specific populations, including pregnant women and HIV co-infected patients, are crucial. Addressing HBV-associated nephropathy requires enhanced surveillance, timely antiviral intervention, and tailored therapeutic approaches to improve patient outcomes. Graphical abstract